Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

RCT (n=831) found radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival (median, 8.7 vs. 3.4 months; HR 0.40; 99.2% CI, 0.29 to 0.57; p<0.001) and overall survival (15.3 vs. 11.3 months; 0.62; 0.52 to 0.74; p<0.001) when added to standard care

Source:

New England Journal of Medicine